Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 2Diagnosis: Prostate CancerNCT ID: NCT02028988
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-444
This research study is evaluating a drug called enzalutamide in combination with external beam radiation therapy as a possible treatment for prostate cancer. Presently, when participants receive hormonal therapy with radiation therapy for prostate cancer, medications are given to reduce testosterone levels in the blood stream. This leads to side effects such as loss of sex drive, erectile dysfunction (ED) and decrease in muscle strength. The purpose of this study is test another form of hormonal therapy with radiation therapy. The medication called enzalutamide will be used with radiation therapy. Instead of lowering testosterone, enzalutamide blocks testosterone in cells. This study will test if enzalutamide when used with radiation will lower the PSA without causing the side effects associated with medications that lower testosterone in the blood stream.
Conducting Institutions: Beth-Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Brigham and Women's Hospital, DF/BWCC at South Shore Hospital
Overall PI: Glenn Bubley, MD,
Beth Israel Deaconess Medical Center
Site-responsible Investigators: Paul Nguyen, MD,
Brigham and Women's Hospital
Contacts: Dana-Farber Cancer Institute:
Judith Prisby, 617-632-5068,
firstname.lastname@example.orgDana-Farber Cancer Institute:
Amanda Fredericks, 617-632-5514,
email@example.comDana-Farber Cancer Institute:
Meghara Walsh, 617-632-5264,
firstname.lastname@example.orgBeth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060